drugset / Trial / NCT05293171
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
RandomizedCrossoverTriple-blindOther
Summary
The study will assess the corrected QT (QTc) effects (electrocardiogram \[ECG\]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative to placebo in approximately 40 healthy subjects.
Timeline
- Start
- 2021-06-11
- Primary completion
- 2022-06-01
- Completion
- 2022-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Motixafortide | Peptide | 1.25 mg/kg | Subcutaneous |
| Subject | Motixafortide | Peptide | 2 mg/kg | Subcutaneous |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.